A calm look at the cost of various brands of antiasthmatic drugs available in India

Mir, Shakeel Ahmad

doi:10.18203/2319-2003.ijbcp20160116

Cited by 3 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Similar results were found by Mir SA in two different cost analysis studies. 8,13 The treatment of chronic illnesses commonly includes the long-term use of drugs. Although these medications are effective in combating disease, their full benefits are often not realized because approximately 50% of patients do not take their medications as prescribed.…”

Section: Discussionmentioning

confidence: 99%

“…Offline sources utilized were: latest issues of drug today, CIMS and MIMS, and online sources utilized were: "Pharma Sahi Dam" of National Pharmaceutical Authority of Government of India, "G-Dawa" of Health and family Welfare Department of Government of Gujarat, "India Drug Index" and "Drug Brands". 8 1. The minimum and the maximum cost in Rupees(INR) of a particular antihypertensive drug manufactured by various pharmaceutical companies in the same strength were noted.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cost variation analysis of different brands of commonly prescribed antihypertensive drugs, available in Indian market: a pharmacoeconomic study

Mir

2018

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

consideration of cost of treatment is an important aspect of health economics. The cost of drug is an important factor, especially in developing countries. 2 The most basic cost of a drug is reflected in the acquisition price from a supplier. There are three types of costs associated with medicines in health care system: direct, indirect and intangible. These ABSTRACT Background: Worldwide, Hypertension is estimated to cause 7.5 million deaths, about 12.8% of the total of all deaths. This accounts for 57 million disability adjusted life years (DALYS) or 3.7% of total DALYS. Globally, the overall prevalence of hypertension in adults aged 25 and over was around 40% in 2008.Despite its benefits, treatment of hypertension is costly. Direct medical spending to treat hypertension totalled $42.9 billion in 2010, with almost half ($20.4 billion) in the form of prescription medications. Being, a silent disease, adherence to antihypertensive drugs is poor. One of the important factors of poor adherence to antihypertensives is the cost of the drugs. There is wide cost variation among different brands of the same antihypertensive drug. Clinician's awareness of cost of therapeutics is poor. The costly brand of same generic drug is proved to be in no way superior to its economically cheaper counterpart. Methods: The minimum and the maximum cost in Rupees (INR) of a particular antihypertensive agent manufactured by various pharmaceutical companies in the same strength were noted. The cost of 10 tablets/capsules was calculated. The cost ratio and percent cost variation were calculated for each brand. Results: The cost variation observed in the present study was as high as 2337.50 % for Hydralazine. Other significantly high cost variations found in the present study were: 1315.25%

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Cost variation analysis of different brands of commonly prescribed antihypertensive drugs, available in Indian market: a pharmacoeconomic study

Mir

2018

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…They lack access because prices are high and their purchasing power is low. 10 In India, patients are paying out of their pockets for their medical bills and are not covered by insurance schemes, unlike developed countries. In this situation, it is prudent to revisit the costing mechanisms and the huge difference between the pricing of brands have to be regulated by concerned agencies.…”

Section: Discussionmentioning

confidence: 99%

Study of variation in prices of oral antiplatelet drugs available in Indian market

Rashmi

Nerlekar

Rajeev³

2016

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

“…The parameters included in this study were: (1) the minimum and maximum cost: the minimum and the maximum cost in rupees (₹) of a particular antihypertensive drug manufactured by various pharmaceutical companies in the same strength were noted; (2) the cost ratio: it is the ratio of the cost of the costliest to cheapest brand of a drug which tells, how many times costliest brand costs more than the cheapest one; (3) percentage cost variation: it was calculated as follows, 12 % cost variation= − × 100.…”

Section: Methodsmentioning

confidence: 99%

A pharmacoeconomic study of different brands of commonly prescribed antihypertensive drugs

Upasani

Barve

Hiray

2021

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: The hypertension is the most common chronic disease, therefore treatment should be affordable. The antihypertensive drugs of same strength are available in market at different costs. This study was undertaken to create awareness among health care workers and patients, about cost difference among different brands of same antihypertensive drug. So that whenever possible, a cheaper effective brand can be prescribed to ensure better patient adherence.Methods: Maximum retail price (MRP) of various antihypertensive drugs of same strength, manufactured by different pharmaceutical companies was obtained from various offline and online sources. The minimum and maximum cost of 10 tablets/capsules noted. The cost ratio and percentage cost variation was calculated for single drug and fixed dose combinations. The ceiling price (as per DPCO) of essential antihypertensives (as per national list of essential medicines) was compared with their maximum cost.Results: The formulations of single antihypertensive drugs (41) and fixed dose combinations of two drugs (19) and three drugs (9) were included in the study. Among the single antihypertensives analyzed the highest cost difference was of eplerenone (50 mg) and high cost ratio and cost variation percentage was of amlodipine (5 mg). Among fixed dose combination of two drugs analyzed highest cost difference was found that of hydrochlorothazide (12.5 mg)+olmesartan (40 mg) combination and highest cost ratio and percentage cost variation was of amlodipine (5 mg)+telmisartan (40 mg).Conclusions: There was a huge price variation among the antihypertensive drugs manufactured by various companies. Some measures must be taken by the government to bring the uniformity in the price that will help to reduce the economic burden on the patients.

show abstract

A calm look at the cost of various brands of antiasthmatic drugs available in India

Cited by 3 publications

References 4 publications

Cost variation analysis of different brands of commonly prescribed antihypertensive drugs, available in Indian market: a pharmacoeconomic study

Cost variation analysis of different brands of commonly prescribed antihypertensive drugs, available in Indian market: a pharmacoeconomic study

Study of variation in prices of oral antiplatelet drugs available in Indian market

A pharmacoeconomic study of different brands of commonly prescribed antihypertensive drugs

Contact Info

Product

Resources

About